Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

CIPhotos Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a precision oncology company targeting genetically defined cancers. It calls its approach the Masterkey approach, which aims to provide one solution for many types of cancer mutations and address the disease in a much broader range of patients than current precision therapies can access. Its oral therapies are designed to target families of oncogenic mutations including drug-resistant mutations, and are also designed to cross the blood-brain bar ...